Deep targeted sequencing of circulating tumor DNA to inform treatment in patients with metastatic castration-resistant prostate cancer.

J Exp Clin Cancer Res · 2025 · PMC11998381 · PMID 40229848

Europe PMC DOI

hedged sentences

0.0510

closest p · 1.0× alpha

0.0800

boldest claim

The sentences

borderline significantp = 0.051so close (0.05 < p ≤ 0.1)

2 A) and were borderline significant after adjustment for ctDNA% (HR = 2.73, 95% CI: 1.31–6.55, BH adj. p = 0.051, Fig. 2 A).

also in 11,409 other papers

did not reach statistical significancep = 0.08so close (0.05 < p ≤ 0.1)

dataset, with BRAF alterations and CHD1 loss only being identified in patients with primary resistance to first-line treatment with enzalutamide or abiraterone, although this did not reach statistical significance (both p = 0.08, Fisher’s exact test, Fig. 3C).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.